Does Cobenfy Have the Potential to Become a Top Drug for BMY?

Key Takeaways Bristol Myers gained FDA approval for Cobenfy in schizophrenia in September 2024.Cobenfy posted $62M in 1H 2025 sales, with higher sales expected in 2H.BMY is testing Cobenfy in Alzheimers and bipolar 1 disorder to broaden use.Bristol Myers (BMY) won FDA approval for xanomelineand trospiumchloride (formerly KarXT), an oral medication for the treatment of schizophrenia in adults, in September 2024.The drug was approved under the brand name Cobenfy.The approval of Cobenfyfor schizophrenia broade ...